Search Results - "Wallentin, Lars"

Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease by Wollert, Kai C, Kempf, Tibor, Wallentin, Lars

“…Growth differentiation factor 15 (GDF-15) is expressed and secreted in response to inflammation, oxidative stress, hypoxia, telomere erosion, and oncogene…”
Get full text

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials by Costa, Francesco, MD, van Klaveren, David, MSc, James, Stefan, Prof, Heg, Dik, PhD, Räber, Lorenz, MD, Feres, Fausto, MD, Pilgrim, Thomas, MD, Hong, Myeong-Ki, Prof, Kim, Hyo-Soo, MD, Colombo, Antonio, MD, Steg, Philippe Gabriel, Prof, Zanchin, Thomas, MD, Palmerini, Tullio, MD, Wallentin, Lars, Prof, Bhatt, Deepak L, Prof, Stone, Gregg W, Prof, Windecker, Stephan, Prof, Steyerberg, Ewout W, Prof, Valgimigli, Marco, Prof

“…Summary Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after coronary stenting, but increases…”
Get full text

EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials by Wallentin, Lars, Gale, Chris P, Maggioni, Aldo, Bardinet, Isabel, Casadei, Barbara

Get full text

Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK by Chung, Sheng-Chia, PhD, Gedeborg, Rolf, MD, Nicholas, Owen, PhD, James, Stefan, MD, Jeppsson, Anders, Prof, Wolfe, Charles, Prof, Heuschmann, Peter, MD, Wallentin, Lars, Prof, Deanfield, John, Prof, Timmis, Adam, Prof, Jernberg, Tomas, Dr, Hemingway, Harry, Prof

“…Summary Background International research for acute myocardial infarction lacks comparisons of whole health systems. We assessed time trends for care and…”
Get full text

Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes by Bekwelem, Wobo, Connolly, Stuart J, Halperin, Jonathan L, Adabag, Selcuk, Duval, Sue, Chrolavicius, Susan, Pogue, Janice, Ezekowitz, Michael D, Eikelboom, John W, Wallentin, Lars G, Yusuf, Salim, Hirsch, Alan T

“…BACKGROUND—Nonvalvular atrial fibrillation is a major cause of thromboembolic events. In comparison with atrial fibrillation–related stroke, extracranial…”
Get full text

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial by Sandhu, Roopinder K, Ezekowitz, Justin, Andersson, Ulrika, Alexander, John H, Granger, Christopher B, Halvorsen, Sigrun, Hanna, Michael, Hijazi, Ziad, Jansky, Petr, Lopes, Renato D, Wallentin, Lars

“…The prognostic implication of adiposity on clinical outcomes in atrial fibrillation (AF) patients treated with oral anticoagulation is unclear. A total of 17…”
Get full text

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study by Hijazi, Ziad, Dr, Oldgren, Jonas, PhD, Lindbäck, Johan, MSc, Alexander, John H, Prof, Connolly, Stuart J, Prof, Eikelboom, John W, MD, Ezekowitz, Michael D, Prof, Held, Claes, PhD, Hylek, Elaine M, Prof, Lopes, Renato D, PhD, Siegbahn, Agneta, Prof, Yusuf, Salim, Prof, Granger, Christopher B, Prof, Wallentin, Lars, Prof

“…Summary Background The benefit of oral anticoagulation in atrial fibrillation is based on a balance between reduction in ischaemic stroke and increase in major…”
Get full text

Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014 by Szummer, Karolina, Wallentin, Lars, Lindhagen, Lars, Alfredsson, Joakim, Erlinge, David, Held, Claes, James, Stefan, Kellerth, Thomas, Lindahl, Bertil, Ravn-Fischer, Annica, Rydberg, Erik, Yndigegn, Troels, Jernberg, Tomas

“…Abstract Aims We assessed the changes in short- and long-term outcomes and their relation to implementation of new evidence-based treatments in all patients…”
Get full text

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy by Sumaya, Wael, Wallentin, Lars, James, Stefan K, Siegbahn, Agneta, Gabrysch, Katja, Bertilsson, Maria, Himmelmann, Anders, Ajjan, Ramzi A, Storey, Robert F

“…Abstract Aims To determine whether fibrin clot properties are associated with clinical outcomes following acute coronary syndrome (ACS). Methods and results…”
Get full text

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation by Hijazi, Ziad, Lindbäck, Johan, Alexander, John H, Hanna, Michael, Held, Claes, Hylek, Elaine M, Lopes, Renato D, Oldgren, Jonas, Siegbahn, Agneta, Stewart, Ralph A H, White, Harvey D, Granger, Christopher B, Wallentin, Lars

“…Atrial fibrillation (AF) is associated with an increased risk of stroke, which is currently estimated by clinical characteristics. The cardiac biomarkers…”
Get full text

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial by Valgimigli, Marco, Costa, Francesco, Lokhnygina, Yuliya, Clare, Robert M, Wallentin, Lars, Moliterno, David J, Armstrong, Paul W, White, Harvey D, Held, Claes, Aylward, Philip E, Van de Werf, Frans, Harrington, Robert A, Mahaffey, Kenneth W, Tricoci, Pierluigi

“…Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases bleeding to a similar extent. We sought to…”
Get full text

Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study by Wallentin, Lars, Eriksson, Niclas, Olszowka, Maciej, Grammer, Tanja B, Hagström, Emil, Held, Claes, Kleber, Marcus E, Koenig, Wolfgang, März, Winfried, Stewart, Ralph A H, White, Harvey D, Åberg, Mikael, Siegbahn, Agneta

“…Circulating biomarkers are associated with the development of coronary heart disease (CHD) and its complications by reflecting pathophysiological pathways…”
Get full text

Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study by Healey, Jeff S, Dr, Oldgren, Jonas, MD, Ezekowitz, Michael, Prof, Zhu, Jun, MD, Pais, Prem, Prof, Wang, Jia, Msc, Commerford, Patrick, MD, Jansky, Petr, MD, Avezum, Alvaro, MD, Sigamani, Alben, MD, Demasceno, Albertino, MD, Reilly, Paul, PhD, Grinvalds, Alex, BSc, Nakamya, Juliet, PhD, Aje, Akinyemi, MD, Almahmeed, Wael, MD, Moriarty, Andrew, MD, Wallentin, Lars, Prof, Yusuf, Salim, Prof, Connolly, Stuart J, Prof

“…Summary Background Atrial fibrillation is an important cause of morbidity and mortality worldwide, but scant data are available for long-term outcomes in…”
Get full text

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial by Wallentin, Lars, Prof, Yusuf, Salim, Prof, Ezekowitz, Michael D, Prof, Alings, Marco, MD, Flather, Marcus, MD, Franzosi, Maria Grazia, PhD, Pais, Prem, Prof, Dans, Antonio, Prof, Eikelboom, John, MD, Oldgren, Jonas, MD, Pogue, Janice, PhD, Reilly, Paul A, PhD, Yang, Sean, MSc, Connolly, Stuart J, Prof

“…Summary Background Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of…”
Get full text

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome by Alexander, John H, Lopes, Renato D, James, Stefan, Kilaru, Rakhi, He, Yaohua, Mohan, Puneet, Bhatt, Deepak L, Goodman, Shaun, Verheugt, Freek W, Flather, Marcus, Huber, Kurt, Liaw, Danny, Husted, Steen E, Lopez-Sendon, Jose, De Caterina, Raffaele, Jansky, Petr, Darius, Harald, Vinereanu, Dragos, Cornel, Jan H, Cools, Frank, Atar, Dan, Leiva-Pons, Jose Luis, Keltai, Matyas, Ogawa, Hisao, Pais, Prem, Parkhomenko, Alexander, Ruzyllo, Witold, Diaz, Rafael, White, Harvey, Ruda, Mikhail, Geraldes, Margarida, Lawrence, Jack, Harrington, Robert A, Wallentin, Lars

“…In a randomized trial, patients with an acute coronary syndrome were assigned to receive apixaban or placebo in addition to standard therapy. The apixaban…”
Get full text

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial by Wallentin, Lars, Prof, James, Stefan, MD, Storey, Robert F, MD, Armstrong, Martin, PhD, Barratt, Bryan J, PhD, Horrow, Jay, MD, Husted, Steen, MD, Katus, Hugo, Prof, Steg, P Gabriel, Prof, Shah, Svati H, MD, Becker, Richard C, Prof

“…Summary Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of…”
Get full text

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale by Lopes, Renato D., MD, PhD, Alexander, John H., MD, MHS, Al-Khatib, Sana M., MD, MHS, Ansell, Jack, MD, Diaz, Raphael, MD, Easton, J. Donald, MD, Gersh, Bernard J., MB, ChB, DPhil, Granger, Christopher B., MD, Hanna, Michael, MD, Horowitz, John, MD, Hylek, Elaine M., MD, MPH, McMurray, John J.V., MD, Verheugt, Freek W.A., MD, PhD, Wallentin, Lars, MD, PhD

“…Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vitamin K antagonists (VKAs). Vitamin K antagonist use is…”
Get full text

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis by Andreotti, Felicita, Rocca, Bianca, Husted, Steen, Ajjan, Ramzi A, ten Berg, Jurrien, Cattaneo, Marco, Collet, Jean-Philippe, De Caterina, Raffaele, Fox, Keith A A, Halvorsen, Sigrun, Huber, Kurt, Hylek, Elaine M, Lip, Gregory Y H, Montalescot, Gilles, Morais, Joao, Patrono, Carlo, Verheugt, Freek W A, Wallentin, Lars, Weiss, Thomas W, Storey, Robert F

Get full text

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial by Diener, Hans-Christoph, Prof, Connolly, Stuart J, Prof, Ezekowitz, Michael D, Prof, Wallentin, Lars, Prof, Reilly, Paul A, PhD, Yang, Sean, MSc, Xavier, Denis, MD, Di Pasquale, Giuseppe, Prof, Yusuf, Salim, Prof

“…Summary Background In the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, dabigatran reduced occurrence of both stroke and…”
Get full text

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation by Flack, Kathryn F, Desai, Jay, Kolb, Jennifer M, Chatterjee, Prapti, Wallentin, Lars C, Ezekowitz, Michael, Yusuf, Salim, Connolly, Stuart, Reilly, Paul, Brueckmann, Martina, Ilgenfritz, John, Aisenberg, James

“…Background & Aims Gastrointestinal (GI) bleeding in patients receiving anticoagulation agents can be caused by occult malignancies. We investigated the…”
Get full text